Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Conditions
- Adult Alveolar Soft Part Sarcoma
- Adult Angiosarcoma
- Adult Desmoplastic Small Round Cell Tumor
- Adult Epithelioid Hemangioendothelioma
- Adult Epithelioid Sarcoma
- Adult Extraskeletal Myxoid Chondrosarcoma
- Adult Extraskeletal Osteosarcoma
- Adult Fibrosarcoma
- Adult Leiomyosarcoma
- Adult Liposarcoma
- Adult Malignant Mesenchymoma
- Adult Malignant Peripheral Nerve Sheath Tumor
- Adult Rhabdomyosarcoma
- Adult Synovial Sarcoma
- Adult Unclassified Pleomorphic Sarcoma
- Chondrosarcoma
- Clear Cell Sarcoma of the Kidney
- Conjunctival Kaposi Sarcoma
- Dermatofibrosarcoma Protuberans
- Gastrointestinal Stromal Tumor
- Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Metastatic Osteosarcoma
- Ovarian Sarcoma
- Recurrent Adult Soft Tissue Sarcoma
- Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Recurrent Kaposi Sarcoma
- Recurrent Osteosarcoma
- Recurrent Uterine Corpus Sarcoma
- Small Intestine Leiomyosarcoma
- Stage III Adult Soft Tissue Sarcoma
- Stage III Uterine Sarcoma
- Stage IV Adult Soft Tissue Sarcoma
- Stage IV Uterine Sarcoma
- Unclassified Pleomorphic Sarcoma of Bone
Interventions
- DRUG: Gamma-Secretase Inhibitor RO4929097
- OTHER: Laboratory Biomarker Analysis
- OTHER: Pharmacological Study
- DRUG: Vismodegib
Sponsor
National Cancer Institute (NCI)